MorphoSys, based in Martinsreid near Munich, has been around for a full 27 years, and was until this year led by its co-founder Simon Moroney. He oversaw the patient and painstaking development of the company’s R&D expertise over those decades. The strategy first focused on providing its next-generation antibody technology to big pharma, but MorphoSys now possesses an impressive pipeline of partnered and in-house molecules.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
